ABSTRACT We have investigated the role of angiotensin converting enzyme (ACE) in the development of pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular disease in rats given a single subcutaneous injection of the pyrrolizidine alkaloid monocrotaline. Thirty-six young female Wistar rats were divided into a test group of 27 animals and a control group of nine animals. Each test rat was given a single subcutaneous injection of monocrotaline (60 mg/kg body weight). On the first, third, fifth, seventh, tenth, twelfth, fourteenth, seventeenth, and twenty-second days after the injection of monocrotaline the mean right ventricular systolic blood pressure was measured in one control and three test rats. The animals were then killed and we measured the specific activity of ACE in serum and lung homogenate. We also evaluated muscularisation of pulmonary arterioles, medial hypertrophy of muscular pulmonary arteries, and right ventricular hypertrophy. The sequence of changes was as follows: muscularisation of pulmonary arterioles and medial hypertrophy of muscular pulmonary arteries were apparent seven days after administration of monocrotaline; pulmonary hypertension and reduced lung ACE activity occurred after 10 days; right ventricular hypertrophy was detected after 12 days. Serum ACE activity was unchanged. If is concluded that the reduction in lung ACE activity is a result rather than a cause of the pulmonary hypertension. This reduction in lung ACE activity may be a protective mechanism designed to limit the elevation of the pulmonary arterial pressure.
Monocrotaline is a pyrrolizidine alkaloid present in the seeds and foliage of the leguminous plant Crotalaria spectabilis. The administration of this alkaloid to rats produces pulmonary hypertension, hypertensive pulmonary vascular disease and right ventricular hypertrophy. 1 The pulmonary vascular lesions comprise thickening of the pulmonary trunk, medial hypertrophy of muscular pulmonary arteries, and muscularisation of pulmonary arterioles. In about one-third of rats there is also an acute necrotising pulmonary arteritis. The mechanism whereby monocrotaline causes elevation of the pulmonary arterial pressure is unknown. Recently we showed that the activity of angiotensin converting enzyme (ACE) was significantly reduced in lung tissue homogenates derived from rats with pulmonary hypertension produced by subcutaneous injection of monocrotaline.2 Furthermore, the reduction in lung ACE activity was inversely proportional to the severity of pulmonary hypertension and right ventricular hypertrophy. ACE is an exopeptidase that catalyses the hydrolytic removal of carboxyterminal dipeptide residues from polypeptide substrates.3 Two such reactions of ACE may participate in the regulation of blood pressure. First, it converts the inactive decapeptide angiotensin I to the potent vasoconstrictive octapeptide angiotensin II. Secondly, it inactivates the vasodilator nonapeptide bradykinin. The role of ACE and angiotensin II in the humoral control of the pulmonary circulation is not clear. Accordingly, we have studied serum and lung ACE activity during the development of pulmonary hypertension in rats given a single subcutaneous injection of monocrotaline. We wished to determine the temporal relationship between decreased lung ACE activity on one hand, and pulmonary hypertension, right ventricular hypertrophy, medial hypertrophy of muscular pulmonary arteries, and 88 group.bmj.com on April 5, 2017 -Published by http://thorax.bmj.com/ Downloaded from muscularisation of pulmonary arterioles on the other hand.
Methods
Thirty-six female Wistar rats (initial body weight 113 g ± 11 SD) were divided into a test group of 27 animals and a control group of nine animals. Each test rat was given a single subcutaneous injection of a 2% aqueous solution of monocrotaline hydrochloride. The dose of monocrotaline was 60 mg/kg body weight. On the first, third, fifth, seventh, tenth, twelfth, fourteenth, seventeenth, and twenty-second days after the injection of monocrotaline the mean right ventricular systolic blood pressure (Prvs) was measured in one control and three test rats. Under light ether anaesthesia the right external jugular vein was exposed and cannulated, using a modified 21-gauge disposable needle measuring 0 7 mm in external diameter and 3A4 cm in length. The tip of the cannula was guided through the right atrium and tricuspid valve into the right ventricle. The pressure was measured using a Hewlett Packard transducer (1280C) attached to a pressure coupler (8805C) and thermotip recorder (7702B). After measurement of Prvs the abdomen was opened and a sample of blood was obtained from the inferior vena cava. The serum was separated and stored at -20°C before ACE assay using the method described below. The rats were then killed. The cervical and thoracic organs were removed in one block. The left main bronchus was clamped and ligated after which the left lung was removed, washed in ice-cold physiological saline and stored at -20°C to await ACE assay. The trachea was cannulated and the right lung was distended by injecting 7 ml of 10% formol saline which ensured that the pleural surfaces were smooth. The trachea was then ligated, the cannula withdrawn, and the remaining thoracic viscera immersed in 10% formol saline until fixation was complete. The hearts were dissected and weighed using a Sartorius semi-micro analytical balance. Right ventricular hypertrophy was evaluated by expressing the weight of the free wall of the right ventricle (RV) as a percentage of the weight of the left ventricle and interventricular septum (LV+S). A block of tissue was cut from each of the superior, middle, inferior, and median lobes of the right lung of every animal and was routinely processed for histological examination. Sections were stained with haematoxylin and eosin, by the martius-scarlet-blue method for fibrin4 and also by the Miller elastic-Van Gieson method5 for distinguishing smooth muscle, collagen, and elastic tissue. Sections stained by the latter method were used for the assessment of muscularisation of pulmonary arterioles and measurement of medial thickness of muscular pulmonary arteries as described below.
MUSCULARISATION OF PULMONARY ARTERIOLES
The pulmonary arteriole in a rat is an arterial vessel less than 20 ,um external diameter whose wall is normally devoid of smooth muscle except adjacent to its origin from a muscular pulmonary artery. It consists of a single elastic lamina lined by endothelium (fig 1) . Pulmonary venules are structurally identical to pulmonary arterioles, and these cannot be distinguished from one another unless they can be traced to a larger vessel. In chronic pulmonary hypertension the pulmonary arterioles become muscularised with the development of a thick medial coat of circularly orientated smooth muscle bounded by internal and external elastic laminae (fig 2) . Thus they resemble muscular pulmonary arteries in structure. We used the technique of Hunter et it avoided error in the measurement of the diameter. The external diameter was taken as the mean of two measurements, at right angles to each other, of the distance between diametrically opposite points on the external elastic lamina. The medial thickness was estimated as the mean of four measurements taken at approximately equally spaced points around the vessel wall. From these data medial thickness was expressed as a percentage of the external diameter of the vessel. A value for the average percentage medial thickness in each animal was obtained by totalling all the percentages of medial thickness, and dividing the sum by the number of vessels examined. The sections were coded and examined without knowledge as to whether they were derived from control or test animals.
ASSAY OF ACE
The specific activity of ACE was measured in serum and lung homogenate using a modification7 of the spectrophotometric assay described by Cushman and Cheung.8 This method measures the rate of production of hippuric acid from hippuryl-Lhistidyl-L-leucine. Before assay the left lung was thawed, weighed using a Sartorius semi-micro analytical balance, diced by hand, and then homogenised in a Brinkman Polytron 
Results

QUALITATIVE MICROSCOPIC FINDINGS
The lungs of the nine control rats were normal and specifically devoid of pneumonic changes. The groups of three test rats killed on the first, third, fifth, and seventh days after receiving monocrotaline had histologically normal lungs. One of the three test rats killed on the tenth day showed a mild proliferation of large intra-alveolar cells resembling granular pneumocytes.11 One of the three test rats killed on day 12 was unremarkable. The other two showed a mild proliferation of intra-alveolar cells associated with scanty foci of intra-alveolar fibrinous exudate. All three test rats killed on day 14 showed a proliferation of large intra-alveolar cells. Foci of intra-alveolar fibrinous exudate were also present in one of these rats. All three test rats killed on day 17 showed a proliferation of large intra-alveolar cells. In addition, two of these rats showed foci of intraalveolar fibrinous exudate. All three test rats killed on day 22 showed a proliferation and enlargement of intra-alveolar cells together with capillary fibrin thrombi. In addition, two of these rats showed foci of intra-alveolar fibrinous exudate. None of the 27 test rats which received monocrotaline showed evidence of necrotising pulmonary arteritis.
QUANTITATIVE OBSERVATIONS
In the table are listed the results of the assessment of muscularisation of pulmonary arterioles (PVTEL), medial thickness of muscular pulmonary arteries, right ventricular hypertrophy (RV/(LV + S) %), Prvs, and the specific activity of ACE in lung tissue homogenate and serum. The mean numbers of small pulmonary blood vessels examined for evidence of muscularisation in the nine control and 27 test rats were 396±65 and 410 ± 70, respectively. The mean number of muscular pulmonary arteries measured in the nine control rats was 15 ± 4. The mean number of muscular pulmonary arteries and muscularised pulmonary arterioles measured in the 27 test rats was 34 ± 17. All the test rats examined 12 or more days after receiving monocrotaline had developed muscularisation of the pulmonary arterioles, medial thickening of the muscular pulmonary arteries (fig 4) , right ventricular hypertrophy, pulmonary hypertension, and a reduction in lung ACE activity. However, Presumably the vascular lesions lead to the development of pulmonary hypertension which in turn is followed by right ventricular hypertrophy. It seems that the reduction in lung ACE activity is a result rather than a cause of the pulmonary hypertension. ACE has been found in association with the microvascular beds of many tissues including the spleen, pancreas, adrenal, liver, and kidney.12 However, it has been calculated that most of the ACE activity in the body occurs in the lungs13 where the enzyme has been localised on the luminal surface of pulmonary endothelial cells,'4 particularly in relation to flask-shaped indentations called caveolae intracellulares (fig 6) . The caveolae represent a specialised In 1976 Oparil and her co-workers studied serum ACE activity in patients with sarcoidosis, chronic obstructive pulmonary disease, and shock lung. 16 The patients with sarcoidosis had increased ACE activity while those with chronic obstructive pulmonary disease and shock lung had decreased activity in the serum. They suggested that serum ACE activity is a reflection of pulmonary ACE activity. Our results do not support this concept.
Our rats with pulmonary hypertension induced by monocrotaline had decreased lung ACE activity with normal levels in the serum. In a previous paper we showed that rats with pulmonary hypertension due to chronic hypobaric hypoxia also had decreased lung ACE activity with normal levels in the serum.2 In experimental acute lung injury caused by thiourea'7 and paraquat'8 there is an elevation of serum ACE activity which corresponds to a reduction in lung ACE activity. However, these changes are transient and last between one and two hours. Presumably acute injury to the pulmonary capillary endothelial cells causes ACE to be released from the lung into the blood. It has been reported that a single subcutaneous injection of monocrotaline (60 mg/kg body weight) caused ultrastructural evidence of interstitial alveolar oedema and swelling of alveolar capillary endothelial cells within 24 h in young male Sprague-Dawley rats.19 If such changes did occur in our animals then they were not accompanied by changes in lung or serum ACE levels. We did not examine the lungs of our rats with the electron microscope but no histological abnormality was detected until the tenth day after monocrotaline administration when one animal showed a mild proliferation of large intra-alveolar cells resembling granular pneumocytes.11 This non-specific reaction of the lung to injury was noted three days after muscularisation of pulmonary arterioles and medial hypertrophy of muscular pulmonary arteries had first been observed.
The work reported in this paper appears to be the first systematic study of the time course of the development of pulmonary hypertension and associated pulmonary vascular disease after administration of a single dose of monocrotaline. We found that muscularisation of pulmonary arterioles and medial hypertrophy of muscular pulmonary arteries occurred at seven days followed by pulmonary hypertension at 10 days. Right ventricular hypertrophy was detected after 12 days. Meyrick and her co-workers20 have recently described the development of pulmonary hypertension and associated pulmonary vascular disease in Sprague-Dawley rats fed on a diet containing powdered Crotalaria spectabilis seeds at a concentration of 1 g powdered seed per kg rat food. They found that muscularisation of the small pulmonary arterial vessels and pulmonary hypertension were evident on day 14. Increased medial thickness of muscular pulmonary arteries up to 200 /tm external diameter was detected on day 21 while right ventricular hypertrophy was not apparent until day 28. There are at least three reasons why these results differ from our own. First, Meyrick and her co-workers used male Sprague-Dawley rats weighing between 220 and 240 g whereas we used female Wistar rats weighing 113 g. Secondly, while we gave a precisely measured dose of monocrotaline to our rats, Meyrick and her co-workers merely fed their rats on powdered Crotalaria spectabilis seeds. Accordingly, it is not clear what dose was given to individual rats, and there must have been considerable variation between animals. It has been calculated that a diet containing 0-l % of Crotalaria spectabilis seeds is equivalent to a daily dose of about 10 mg/kg body weight of monocrotaline since the seeds contain about 3 % of the pure alkaloid. 21 We believe that in order to study the evolution of the pulmonary vascular disease it is important to give a definite known dose of monocrotaline at a specific time. Thirdly, Meyrick and her co-workers used a different method to prepare the pulmonary vasculature for examination. This involved deep freezing the lungs for an unstated time followed by thawing and injection of warm micropaque and gelatin under pressure. Huxtable and his co-workers22 placed monocrotaline in the drinking water of rats at a concentration of 20 mg/I for three weeks. It was calculated that the daily dose was 3 6 mg/kg. They stated that right ventricular hypertrophy was present KaYv, Keane, Suyama, Gauthier after two weeks of treatment and the right ventricular blood pressure was significantly elevated after 22 days. Medial hypertrophy of pulmonary arteries was detectable by 14 days and was marked by 21 days. However, the pulmonary vasculature was not evaluated quantitatively. They measured lung ACE activity by perfusing the lung and studying the rate of metabolism of hippuryl-histidyl-leucine. When the rate of metabolism was expressed per dry weight of lung tissue there was apparently a significant decrease in lung ACE activity. However, when the metabolism was expressed as rate per lung then there was no significant reduction. Accordingly, these workers concluded that monocrotaline administration did not impair the activity of ACE in the lung.
The mechanism whereby monocrotaline induces pulmonary hypertension is unknown. Monocrotaline itself is a stable and relatively inactive substance but there is evidence that it is metabolised in the liver to produce a highly reactive unstable pyrrole derivative. 23 Intravenous injection of the pyrrole derivative leads to the development of pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular disease.24 It has been suggested that monocrotaline pyrrole damages the pulmonary capillary endothelium leading to cytoplasmic swelling followed by cellular disruption and subsequent thrombosis with fibrin deposition.24 It was further postulated that the resulting occlusion of alveolar capillaries impedes blood flow leading to pulmonary hypertension accompanied by medial hypertrophy of muscular pulmonary arteries and right ventricular hypertrophy. In our study of the evolution of pulmonary vascular disease, muscularisation of pulmonary arterioles and medial hypertrophy of muscular pulmonary arteries were apparent after seven days and pulmonary hypertension was detectable after 12 days. Fibrin thrombi, however, were not detected in the alveolar capillaries until 22 days after monocrotaline administration. Furthermore, the stated hypothesis does not account for the proliferation of smooth muscle which has been described in the pulmonary veins of rats given Crotalaria spectabilis seeds25 and the pyrrolizidine alkaloid fulvine.26 Alveolar hypoxia, which is known to be associated with pulmonary vasoconstriction, has been invoked as the mechanism responsible for the pulmonary hypertension induced by monocrotaline.27 Alveolar hypoxia also leads to a reduction in lung ACE activity.2 28 However, the histological type of hypertensive pulmonary vascular disease encountered in monocrotaline intoxication is quite different from that which occurs in chronic hypoxic pulmonary hypertension.29 Furthermore, although we did not measure systemic arterial oxygen tension, this was done by Meyrick and her co-workers who found no group.bmj.com on April 5, 2017 -Published by http://thorax.bmj.com/ Downloaded from evidence of systemic arterial hypoxemia.20 A proliferation of mast cells occurs in a proportion of rats treated with monocrotaline.30 Rat mast cells contain serotonin which is known to constrict small pulmonary blood vessels in some animals. It was postulated that monocrotaline or one of its metabolites might stimulate the proliferation of pulmonary mast cells and that the release of serotonin from them might lead to constriction of small pulmonary blood vessels. This hypothesis was especially attractive since it would account for the latent period which elapses between the administration of monocrotaline and the development of pulmonary hypertension. It was found p-chlorophenylalanine which inhibits serotonin synthesis reduced the severity of pulmonary hypertension in rats treated with monocrotaline but did not prevent it completely.3' However, in a more recent study, cinnarizine which inhibits vasoconstriction induced by serotonin did not prolong the survival or reduce the incidence of right ventricular hypertrophy and hypertensive pulmonary vascular disease in rats given a single injection of monocrotaline.32 It has been suggested that the lung mast cell hyperplasia which occurs in rats treated with monocrotaline is not concerned in the genesis of the pulmonary hypertension but is a secondary phenomenon related to the development of exudative lesions in the lung parenchyma.33
In conclusion, the present study has revealed that the sequence of changes occurring in rats given a single injection of monocrotaline is muscularisation of pulmonary arterioles and medial hypertrophy of muscular pulmonary arteries followed by pulmonary hypertension followed by right ventricular hypertrophy. The depression in lung ACE activity occurs after the development of the pulmonary vascular disease and appears at the same time as the pulmonary hypertension. Accordingly, it is considered that decreased lung ACE activity is an effect rather than a cause of the pulmonary hypertension. This reduction in lung ACE activity in pulmonary hypertension may be a protective mechanism designed to limit the elevation of the pulmonary arterial pressure.
